Abstract | BACKGROUND: METHOD: RESULTS: Four weeks after an injection of STZ, the renal 11beta-HSD2 and mRNA levels were significantly lower in diabetic rats than in control rats, and the mean systolic blood pressure was 14.8% higher in diabetic rats than in controls. Subcutaneous injections of spironolactone into diabetic rats for three weeks partially reversed the decrease in renal 11beta-HSD2 activity and gene expression, and prevented the mean systolic blood pressure elevation. Spironolactone treatment for one week also resulted in a significant reduction in mean systolic blood pressure during the development of diabetic hypertension. However, treatment with STZ did not significantly decrease the renal 11beta-HSD1 activity and mRNA expression, and spironolactone treatment did not exert a significant effect on this enzyme in STZ-induced diabetic rats. CONCLUSION:
|
Authors | Y J Liu, Y Nakagawa, K Toya, Y Wang, H Saegusa, T Nakanishi, T Ohzeki |
Journal | Kidney international
(Kidney Int)
Vol. 57
Issue 5
Pg. 2064-71
(May 2000)
ISSN: 0085-2538 [Print] United States |
PMID | 10792625
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- RNA, Messenger
- Receptors, Mineralocorticoid
- Spironolactone
- Aldosterone
- Streptozocin
- Hydroxysteroid Dehydrogenases
- 11-beta-Hydroxysteroid Dehydrogenases
- Corticosterone
|
Topics |
- 11-beta-Hydroxysteroid Dehydrogenases
- Aldosterone
(blood)
- Animals
- Corticosterone
(blood)
- Diabetes Mellitus, Experimental
(physiopathology)
- Hydroxysteroid Dehydrogenases
(genetics, metabolism)
- Male
- RNA, Messenger
(analysis)
- Rats
- Rats, Sprague-Dawley
- Receptors, Mineralocorticoid
(drug effects, physiology)
- Spironolactone
(pharmacology)
- Streptozocin
- Systole
(drug effects)
|